Fmoc-Lys(Tfa)-OHCAS# 76265-69-5 |
- PF-4708671
Catalog No.:BCC5031
CAS No.:1255517-76-0
- BIX 02565
Catalog No.:BCC4303
CAS No.:1311367-27-7
- BI-D1870
Catalog No.:BCC5030
CAS No.:501437-28-1
- CMK
Catalog No.:BCC1489
CAS No.:821794-90-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 76265-69-5 | SDF | Download SDF |
PubChem ID | 16213176 | Appearance | Powder |
Formula | C23H23F3N2O5 | M.Wt | 464.4 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-[(2,2,2-trifluoroacetyl)amino]hexanoic acid | ||
SMILES | C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)NC(CCCCNC(=O)C(F)(F)F)C(=O)O | ||
Standard InChIKey | ZVLMWTPNDXNXSZ-IBGZPJMESA-N | ||
Standard InChI | InChI=1S/C23H23F3N2O5/c24-23(25,26)21(31)27-12-6-5-11-19(20(29)30)28-22(32)33-13-18-16-9-3-1-7-14(16)15-8-2-4-10-17(15)18/h1-4,7-10,18-19H,5-6,11-13H2,(H,27,31)(H,28,32)(H,29,30)/t19-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Fmoc-Lys(Tfa)-OH Dilution Calculator
Fmoc-Lys(Tfa)-OH Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1533 mL | 10.7666 mL | 21.5332 mL | 43.0663 mL | 53.8329 mL |
5 mM | 0.4307 mL | 2.1533 mL | 4.3066 mL | 8.6133 mL | 10.7666 mL |
10 mM | 0.2153 mL | 1.0767 mL | 2.1533 mL | 4.3066 mL | 5.3833 mL |
50 mM | 0.0431 mL | 0.2153 mL | 0.4307 mL | 0.8613 mL | 1.0767 mL |
100 mM | 0.0215 mL | 0.1077 mL | 0.2153 mL | 0.4307 mL | 0.5383 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Fmoc-Lys(Tfa)-OH
- Yukovanol
Catalog No.:BCN3699
CAS No.:76265-12-8
- Piptocarphin A
Catalog No.:BCN4586
CAS No.:76248-63-0
- 15-Hydroxyferruginol
Catalog No.:BCN3294
CAS No.:76235-93-3
- Ehretinine
Catalog No.:BCN1994
CAS No.:76231-29-3
- 5-Deoxycajanin
Catalog No.:BCN4310
CAS No.:7622-53-9
- Piptocarphin F
Catalog No.:BCN6447
CAS No.:76215-53-7
- Derrone
Catalog No.:BCN4587
CAS No.:76166-59-1
- TCPOBOP
Catalog No.:BCC6979
CAS No.:76150-91-9
- Mildronate
Catalog No.:BCC2289
CAS No.:76144-81-5
- TAE684 (NVP-TAE684)
Catalog No.:BCC3660
CAS No.:761439-42-3
- ALK inhibitor 2
Catalog No.:BCC1340
CAS No.:761438-38-4
- TAE226 (NVP-TAE226)
Catalog No.:BCC3885
CAS No.:761437-28-9
- Fmoc-Met(O)-OH
Catalog No.:BCC3530
CAS No.:76265-70-8
- 7-Deoxy-10-hydroxyloganetin
Catalog No.:BCN7578
CAS No.:76267-48-6
- Polyphyllin C
Catalog No.:BCN2587
CAS No.:76296-71-4
- Polyphyllin II
Catalog No.:BCN1052
CAS No.:76296-72-5
- Polyphyllin E
Catalog No.:BCN2588
CAS No.:76296-73-6
- Polyphyllin F
Catalog No.:BCN2589
CAS No.:76296-74-7
- Polyphyllin G
Catalog No.:BCN1054
CAS No.:76296-75-8
- Olaparib (AZD2281, Ku-0059436)
Catalog No.:BCC2206
CAS No.:763113-22-0
- Sodium Nitrite
Catalog No.:BCC4723
CAS No.:7632-00-0
- DL-AP5
Catalog No.:BCC6552
CAS No.:76326-31-3
- Latrunculin A
Catalog No.:BCC7830
CAS No.:76343-93-6
- (1S)-(+)-Menthyl chloroformate
Catalog No.:BCN4972
CAS No.:7635-54-3
Preparation of the very acid-sensitive Fmoc-Lys(Mtt)-OH. Application in the synthesis of side-chain to side-chain cyclic peptides and oligolysine cores suitable for the solid-phase assembly of MAPs and TASPs.[Pubmed:7591489]
Int J Pept Protein Res. 1995 May;45(5):488-96.
N alpha-9-Fluorenylmethoxycarbonyl-N epsilon-4=methyltrityl-lysine, [Fmoc-Lys(Mtt)-OH], was prepared in two steps from lysine, in 42% overall yield. The N epsilon-Mtt function can be quantitatively removed upon treatment with 1% TFA in dichloromethane or with a 1:2:7 mixture of acetic acid/trifluoroethanol/dichloromethane for 30 min and 1 h at room temperature, respectively. Under these conditions, groups of the tert-butyl type and peptide ester bonds to TFA-labile resins, such as the 2-chlorodiphenylmethyl- and the Wang-resin, remained intact. The utility of the new derivative in peptide synthesis has been exemplified with the synthesis of a cyclic cholecystokinin analog. As an example of further application, five types of lysine cores suitable for the solid-phase synthesis of one, two or three epitopes containing antigenic peptides or template-assembled synthetic proteins have been synthesized on Merrifield, Wang and 2-chlorodiphenylmethyl resin.
Solid-phase synthesis of glucose-derived Amadori peptides.[Pubmed:17883244]
J Pept Sci. 2007 Dec;13(12):862-7.
Nonenzymatic glycosylation or glycation of amino groups in peptides and proteins by D-glucose is a universal reaction with important implications for the pathogenesis of many diseases including diabetes mellitus. Here a general approach is reported to synthesize site specifically glucose-derived N-glycated peptides. Therefore, model peptides H-AKASASFL-NH(2), H-AKASADFL-NH(2), H-ASKASKFL-NH(2), and H-AKDSASFL-NH(2) were synthesized on solid phase by Fmoc chemistry using Fmoc-Lys(4-methyltrityl)-OH in positions 2 or 3 to be glycated. After completion of the synthesis, the acid labile 4-methyltrityl-group was cleaved with 1% TFA in DCM and the free amino groups were glycated by the Lobry de Bruyn reaction using 2,3:4,5-di-O-isopropylidene-aldehydo-beta-D-arabino-hexos-2-ulo-2,6-pyranose on solid phase. After TFA treatment, the crude peptides were obtained in high yields and purities above 80%. Minor by-products were well separated on reversed-phase HPLC.
Pegylated peptides. II. Solid-phase synthesis of amino-, carboxy- and side-chain pegylated peptides.[Pubmed:8200730]
Int J Pept Protein Res. 1994 Feb;43(2):127-38.
General procedures are presented for the site-specific pegylation of peptides at the NH2-terminus, side-chain positions (Lys or Asp/Glu) or COOH-terminus using solid-phase Fmoc/tBu methodologies. A model tridecapeptide fragment of interleukin-2, IL-2(44-56)-NH2, was chosen for this study since it possesses several trifunctional amino acids which serve as potential sites for pegylation. The pegylation reagents were designed to contain either Nle or Orn, which served as diagnostic amino acids for confirming the presence of 1 PEG unit per mole of peptide. NH2-Terminal pegylation was carried out by coupling PEG-CH2CO-Nle-OH to the free NH2-terminus of the peptide-resin. Side-chain pegylation of Lys or Asp was achieved by one of two pathways. Direct side-chain pegylation was accomplished by coupling with Fmoc-Lys(PEG-CH2CO-Nle)-OH or Fmoc-Asp(Nle-NH-CH2CH2-PEG)-OH, followed by solid-phase assemblage of the pegylated peptide-resin and TFA cleavage. Alternatively, allylic protective groups were introduced via Fmoc-Lys(Alloc)-OH or Fmoc-Asp(O-Allyl)-OH, and selectively removed by palladium-catalyzed deprotection after assemblage of the peptide-resin. Solid-phase pegylation of the side-chain of Lys or Asp was then carried out in the final stage with PEG-CH2CO-Nle-OH or H-Nle-NH-(CH2)2-PEG, respectively. COOH-Terminal pegylation was achieved through the initial attachment of Fmoc-Orn(PEG-CH2CO)-OH to the solid support, followed by solid-phase peptide synthesis using the Fmoc/tBu strategy. The pegylated peptides were purified by dialysis and preparative HPLC and were fully characterized by analytical HPLC, amino acid analysis, 1H-NMR spectroscopy and laser desorption mass spectrometry.